礼来Eli Lilly & Co. (LLY) 2005年年度报告「NYSE」.pdf

1、Eli Lilly and CompanyAnswers for Shareholders 20052005 Annual Report,Notice of 2006 Annual Meeting,and Proxy StatementYear in Review 1 Financial Highlights 2 Letter to Shareholders 6 Innovation at Lilly:The Portfolio and the Pipeline 8 Board of Directors 10 Senior Management 12 Lilly:Taking Its Role

2、 as a Good Corporate Citizen to HeartFinancials 13 Review of Operations 19 Consolidated Statements of Income 21 Consolidated Balance Sheets 22 Consolidated Statements of Cash Flows 30 Consolidated Statements of Comprehensive Income 31 Segment Information 32 Selected Quarterly Data 33 Selected Financ

3、ial Data 34 Notes to Consolidated Financial Statements 55 Managements Reports 56 Report of Independent Registered Public Accounting Firm Proxy Statement 58 Notice of 2006 Annual Meeting and Proxy Statement 60 General Information 64 Board of Directors 67 Highlights of the Companys Corporate Governanc

4、e Guidelines 74 Audit Committee Matters 76 Executive Compensation 83 Performance Graph 84 Ownership of Company Stock 86 Items of Business To Be Acted Upon at the Meeting 93 Other MattersCorporate Information 94 Corporate Information 95 Annual Meeting Admission Ticket 12005 Financial Highlights ELI L

5、ILLY AND COMPANY AND SUBSIDIARIES(Dollars in millions,except per-share data)Year Ended December 31 2005 2004 Change%Net sales.$14,645.3$13,857.9 6Research and development .3,025.5 2,691.1 12Research and development as a percent of sales .20.7%19.4%Net income .$1,979.6$1,810.1 9Earnings per sharebasi

6、c.1.82 1.67 9Earnings per sharediluted.1.81 1.66 9Reconciling items:1 Product liability charge,primarily related to Zyprexa .90 Asset impairments,restructuring and other special charges .14.38 Cumulative effect of a change in accounting principle.02 Tax expense on the repatriation of earnings under